MICA and MICB can also be upregulated by histone deacetylase inhibitors, which have been explored as therapeutic targets in MCC due to their ability to upregulate both “kill me” signals and class I MHC (61). The gene discussed is MICA; the disease is Merkel cell skin cancer.